Cancer Prevention Pharmaceuticals Inc. (CPP) and its partner, Mallinckrodt plc, said Tuesday the phase III trial of CPP-1X/sulindac in patients with the orphan disease familial adenomatous polyposis (FAP) did not meet its primary endpoint. Mallinckrodt doesn't plan to pursue the program's commercialization.